Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
Select a cancer below for additional information on ORP active trials at NCCN Member Institutions.
| Christos Fountzilas, MD | Roswell Park Comprehensive Cancer Center | A Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO) |
| Amit Mahipal, MBBS, MPH | Mayo Clinic Cancer Center | Phase II Trial of Trifluridine/Tipiracil in Combination with Irinotecan in Biliary Tract Cancers |
| Sarbajit Mukherjee, MD, MS | Roswell Park Comprehensive Cancer Center | Use of Trifluridine/tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction (GEJ) Adenocarcinoma |
| Mihaela Cristea, MD | City of Hope National Medical Center | A Phase I Dose-Escalation Safety and Tolerability Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine in Patients with FRα-positive Recurrent Ovarian, Primary Peritoneal, Fallopian tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC) |
| Shannon Westin, MD | The University of Texas MD Anderson Cancer Center | A Phase II with a Limited Safety Lead-In of Enzalutamide in Combination with Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrial Cancer |
| Aarti Bhatia, MD, MPH | Yale Cancer Center/Smilow Cancer Hospital | Single-Arm Phase II Trial of Dual Inhibition of EGFR with Afatinib and Cetuximab with Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck |
| Yasir Elamin, MD | The University of Texas MD Anderson Cancer Center | Randomized Phase II Trial of Osimertinib with or without Local Consolidation Therapy (LCT) for Patients with EGFR-mutant Metastatic NSCLC (NORTHSTAR) |
| Sally York, MD | Vanderbilt-Ingram Cancer Center | Phase I Trial of Combination Afatinib and Necitumumab in EGFR Mutation Positive NSCLC with Acquired Resistance to First or Third Generation EGFR TKIs |
| Pasi Janne, MD | Dana-Farber/Brigham and Women's Cancer Center/ Massachusetts General Hospital | A Phase 2 Study of Osimertinib in Combination with Selumetinib in EGFR Inhibitor Naïve Advanced EGFR Mutant Lung Cancer |
| Joseph Treat, MD | Fox Chase Cancer Center | TH-138: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab in stage IV non-squamous NSCLC patients who harbor a sensitizing EGFR mutation or have never smoked |